Position in BMY
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$608,179
-$31,617 QoQ
Shares Held
10,555
+0.1% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.26%
of 13F equity value
Holder Rank
#1,421
of 2,506 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in BMY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Stonebrook Private Inc. holds $12,172,247 across 9 Drug Manufacturers - General names. BMY ranks #5 (5.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
3,234 | $3,878,956 | |
| 2 | JNJ |
Johnson & Johnson
|
14,252 | $3,619,580 | |
| 3 | ABBV |
AbbVie Inc.
|
8,522 | $2,144,476 | |
| 4 | MRK |
Merck & Co., Inc.
|
5,341 | $686,318 | |
| 5 | BMY |
Bristol Myers Squibb Co
This page
|
10,555 | $608,179 | |
| 6 | NVS |
Novartis AG
|
2,438 | $382,083 | |
| 7 | AMGN |
Amgen Inc
|
848 | $307,077 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
2,201 | $278,074 |
All Filings in BMY
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $608,179 | 10,555 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $639,796 | 10,549 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $506,334 | 9,387 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $400,037 | 8,870 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $611,861 | 13,218 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $925,950 | 15,182 | Shares | Sole | 2025-04-30 | |
| 2024-12-31 | $856,657 | 15,146 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $769,373 | 14,870 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $692,014 | 16,663 | Shares | Sole | 2024-08-06 | |
| 2024-03-31 | $1,164,318 | 21,470 | Shares | Sole | 2024-05-07 | |
| 2023-12-31 | $1,088,387 | 21,212 | Shares | Sole | 2024-02-13 | |
| No filing history on record for this holder in this stock. | ||||||